Elejalde syndrome

From WikiMD's Medical Encyclopedia

Revision as of 04:38, 22 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Elejalde Syndrome (ES), also known as Neuroectodermal Melanolysosomal Disease, is a rare genetic disorder characterized by a range of physical and neurological abnormalities. The syndrome was first described by Elejalde et al. in 1977, following the observation of symptoms in affected individuals that included severe neurological impairment, hypopigmentation of the skin and hair, and distinctive facial features.

Symptoms and Characteristics

The primary features of Elejalde Syndrome include:

  • Hypopigmentation: Individuals with ES exhibit a marked reduction in melanin, leading to lighter skin, hair, and eye color than unaffected family members.
  • Neurological Impairment: Severe mental retardation, seizures, and muscle hypotonia are common among those affected.
  • Facial Dysmorphology: Distinctive facial features may include a broad nasal bridge, hypertelorism (widely spaced eyes), and epicanthic folds.
  • Growth Retardation: Affected individuals may experience delayed growth and development.

Causes

Elejalde Syndrome is caused by mutations in the MYO5A gene, which plays a crucial role in melanosome transport within melanocytes. The disruption of this process leads to the pigmentary and neurological manifestations observed in ES. The condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Diagnosis

Diagnosis of Elejalde Syndrome is primarily based on clinical observation of the characteristic symptoms. Genetic testing can confirm mutations in the MYO5A gene, providing a definitive diagnosis. Prenatal diagnosis may be available for families with a known history of the syndrome.

Treatment and Management

There is no cure for Elejalde Syndrome, and treatment is supportive and symptomatic. Management strategies may include:

  • Neurological Care: Regular monitoring and treatment of seizures and other neurological symptoms.
  • Physical Therapy: To address muscle hypotonia and promote motor development.
  • Dermatological Care: Skin care recommendations to protect the hypopigmented skin from sun damage.
  • Genetic Counseling: To provide affected families with information about the condition and its inheritance pattern.

Prognosis

The prognosis for individuals with Elejalde Syndrome varies depending on the severity of symptoms. Neurological impairment is typically severe, and affected individuals may require lifelong care and support. Early intervention and supportive therapies can improve the quality of life for those with ES.

See Also

External Links


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.